The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party
- PMID: 1742221
- DOI: 10.1093/oxfordjournals.annonc.a058044
The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party
Abstract
A prognostic model was developed by examination of the prospectively recorded presentation characteristics of patients presenting with low grade non-Hodgkin's lymphomas (LGL). A geographically distinct group (Edinburgh and Borders) was excluded in order to test the validity of the model based on the rest of the Scotland and Newcastle Lymphoma Group (SNLG) population. Between 1979 and 1987 506 patients presented with low grade lymphoma according to Working Formulation definition within one of each of the three main pathology categories. The median available follow-up was 47 months. In a multivariate analysis performance status, age, stage, gender and haemoglobin all contributed separately. 25% of all patients had relatively good prognosis with a median survival not reached and 84% alive at 5 years. Conversely for the worst prognostic group of 25% of patients the median survival is 18 months with only 26% surviving at 5 years. Finally for the intermediate group of 50% of all patients, median survival is 69 months with 58% alive at 5 years. These striking prognostic separations are shown also to be valid in sub-group analysis. Thus young patients within any pathology subgroup have been identified with bad prognostic lymphoma for whom novel strategies in therapy should be devised.
Similar articles
-
A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party.Br J Cancer. 1991 Jun;63(6):945-52. doi: 10.1038/bjc.1991.207. Br J Cancer. 1991. PMID: 2069849 Free PMC article. Clinical Trial.
-
Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.J Clin Oncol. 1994 Oct;12(10):2167-75. doi: 10.1200/JCO.1994.12.10.2167. J Clin Oncol. 1994. PMID: 7931487 Clinical Trial.
-
[Non-Hodgkin's lymphoma in adults: a clinico-pathologic study of 169 cases].J Formos Med Assoc. 1990 Nov;89(11):1017-22, 1015. J Formos Med Assoc. 1990. PMID: 1982122 Chinese.
-
[Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients].Sangre (Barc). 1992 Oct;37(5):337-44. Sangre (Barc). 1992. PMID: 1293772 Review. Spanish.
-
Non-Hodgkin's lymphoma.Curr Probl Cancer. 1996 Jan-Feb;20(1):6-77. doi: 10.1016/s0147-0272(96)80303-5. Curr Probl Cancer. 1996. PMID: 8919170 Review.
Cited by
-
Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience.Radiat Oncol J. 2015 Dec;33(4):310-9. doi: 10.3857/roj.2015.33.4.310. Epub 2015 Dec 30. Radiat Oncol J. 2015. PMID: 26756031 Free PMC article.
-
Prognostic significance of biochemical markers in African Burkitt's lymphoma.Clin Transl Oncol. 2011 Oct;13(10):731-6. doi: 10.1007/s12094-011-0724-8. Clin Transl Oncol. 2011. PMID: 21975335
-
A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma.Med Oncol. 1994;11(1):19-25. doi: 10.1007/BF02990087. Med Oncol. 1994. PMID: 7921924 Clinical Trial.
-
Low-grade lymphomas: new entities and treatment concepts.Med Oncol. 1995 Sep;12(3):131-42. doi: 10.1007/BF01571190. Med Oncol. 1995. PMID: 8852395 Review.
-
Clinical and molecular prognostic factors in follicular lymphoma.Curr Oncol Rep. 2006 Sep;8(5):359-67. doi: 10.1007/s11912-006-0059-8. Curr Oncol Rep. 2006. PMID: 16901397 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials